Donor eggs do not bypass the physical requirements of pregnancy. The person receiving the embryo needs an assessment of their general health, relevant medication, obstetric history and the uterus. A healthy donor profile cannot correct an untreated uterine problem or explain a previous pregnancy complication. The aim is to identify issues that could affect safety, transfer planning or follow-up, not to order the largest possible blood-test package.

Blood group and Rh type, relevant antibodies, infectious-disease assessments and immunity or vaccination review can be part of preconception planning. Thyroid or metabolic testing may be appropriate for particular medical histories. Some results have a time-limited validity period, so the clinic should specify which older reports can be reused. Do not stop prescribed medication or start supplements based on a generic checklist; share your full medication list for review.

A partner sperm sample or donor sperm introduces its own questions. A semen analysis may guide the choice of IVF or ICSI, while infection or genetic assessment follows the relevant clinical programme. Ask whether any known carrier-screening findings in the egg donor and sperm source need to be considered together. A normal semen analysis is useful but does not eliminate every reproductive or genetic concern.

A previous failed cycle is not, by itself, proof of an immune or clotting disorder. Additional investigations may be justified by repeated losses, symptoms or particular findings, but broad testing without a specific indication can add expense and confusion. Ask for a clear explanation of how a positive or negative result would alter management, and whether the investigation is supported by current evidence.

The first consultation should connect the stated concern to a concrete decision. The medical team can review earlier procedures, medication, medical and family history, reproductive investigations and any previous pregnancies. Ask which findings are reassuring, which need clarification and which may change the recommended approach. Rather than repeating every test from a checklist, prioritise investigations whose results could affect safety, treatment selection or timing.

It is appropriate to ask how uncertainty is handled. A result may guide a clinical choice without predicting a personal live birth. For example, an apparently normal scan cannot explain every failed embryo transfer, and a reassuring screening panel cannot exclude every genetic condition. If additional testing is suggested, request its purpose, expected interpretation and a discussion of available alternatives.

Decision point: 1

If you already have detailed treatment records, your first priority is understanding which parts remain valid. An organised record can avoid unnecessary duplication; the physician decides whether further tests are needed.

Decision point: 2

If earlier treatment did not work, bring laboratory and transfer documents rather than relying on a one-line summary. The question is not simply which test is missing, but what your previous pathway reveals.

Decision point: 3

If you will travel from another country, discuss local monitoring, clinic appointments, required consent and the ability to change travel dates. Medical timing should take precedence over flight availability.

Prepare a one-page timeline listing age, relevant medical conditions, medicines, operations, previous pregnancies and fertility procedures. Put dated reports in a clear order: hormone results; ultrasound and uterine imaging; semen analysis; laboratory records; embryo development and transfer reports; genetic findings where available. A count such as “three failed cycles” gives much less clinical detail than the actual stimulation, fertilisation, embryo and transfer records.

If you previously received a particular treatment or medication, include the dose, route, duration and clinical reason when these are known. Avoid sending unlabelled screenshots without a date or laboratory range. Ask the clinical team which documents can be reused and which may need updating. Medical information should be sent only through the secure channels approved by the clinic, with an explanation of confidentiality and consent.

A successful treatment plan connects medical evaluation, laboratory capability, logistical coordination and follow-up. Before treatment, confirm who authorises medication changes, which examinations can be completed locally, how laboratory reports will be shared and what happens if a cycle must be postponed. A comprehensive written plan also explains which decisions can only be made after new results become available.

Try to separate the decision to investigate from the decision to purchase treatment. A remote file review can identify potentially suitable options, but it does not replace examination, formal consent or verification of the local legal requirements. If your circumstances are complicated, requesting a second opinion or counselling before committing is a reasonable part of informed decision-making.

Before buying flights or choosing a treatment date, begin with a structured review of the medical history and any earlier fertility treatments. The most useful first appointment is not a sales call: it identifies the question that needs a clinical answer, reviews what is already known and explains what cannot be decided without examination. A coordinator can help organise the documents, but the medical recommendation must come from the responsible clinician.

The next stage is an individual investigation and timing plan. Some blood tests, imaging or monitoring may be performed locally if their methods and dates are acceptable to the treating team. Results must reach the clinic in readable form, with units, reference ranges and dates. Once the doctor confirms the necessary steps, the team can discuss appointments in Cyprus, possible changes to timing and appropriate follow-up after returning home.

Assisted reproductive care requires more than choosing an attractive option online. Screening, informed consent, clinical suitability and the applicable rules for donor treatment, identity, traceability, storage and family relationships can differ between jurisdictions. A procedure described on an international website may not be legally or clinically available for every applicant. Confirm the position that applies to your treatment and your country of residence before making a financial commitment.

Risks need to be explained in plain language, including uncertainty. A normal screening result cannot exclude every health or genetic risk; embryo transfer does not guarantee a pregnancy, and a positive pregnancy test does not guarantee a live birth. Pregnancy-related risks may remain relevant even when donor gametes are used. No optional investigation or add-on should be presented as universally necessary without a clinical reason and a discussion of evidence.

A useful written quote separates preliminary testing, medication, donor assessment when relevant, laboratory fertilisation, culture, transfer, freezing, storage and any clinically indicated additional procedures. Ask which items are included, optional, excluded or charged if the plan changes. If treatment involves travel, add transport, accommodation, local investigations and time away from work. Comparing only the advertised initial price may obscure major differences in the scope of care.

Discuss cancellation rules, what happens when a cycle is postponed for medical reasons, and whether any unused services are refundable. Ask about the costs of additional monitoring, subsequent transfers or embryo storage if relevant. This is also the right time to clarify what will happen after you travel home, who reads results and whether a local healthcare professional should be involved. Financial clarity is part of informed consent.

Agree in advance who will review results, how quickly urgent concerns should be reported and what clinical care is available locally. When medication or embryo transfer is involved, do not stop or change prescribed medicines based on a forum or an internet timetable. The treating team should give an individual written plan for the next contact, testing and any necessary monitoring.

If treatment does not proceed, the consultation should still end with a usable summary: what was found, which questions remain unanswered and whether another assessment or a different option is reasonable. An unsuccessful cycle also deserves a clear review rather than automatic repetition of every previous step. The patient should have access to the relevant reports and know whom to contact for clarification.